FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年11月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-047 上海昊海生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1.投资者可于 2025 年 12 月 5 日（星期五）15:00-16:00 登录上证路演中心 （https://roadshow.sseinfo.com/），在线参与本次业绩说明会。 2.为提高交流效率，公司现提前向投资者征集问题，欢迎广大投资者于 2025 年 12 月 4 日（星期四）16:00 前登录上证路演中心网站首页，点击"提问预征集" 栏目（https://roadshow.sseinfo.com/preCallQa），根据活动时间，选中本次活动或 将有关问题通过电子邮件方式发送至公司邮箱（info@3healthcare.com），公司将 在业绩说明会上对投资者普遍关注的问题进行回答。 重要内容提示： 一、说明会类型 上海昊海生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日在上海证 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年11月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has experienced a decline of 17.01% year-to-date, with a recent drop of 2.00% on November 26, 2023, indicating potential challenges in the company's market performance [1]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down 10.63% compared to the previous year [2]. - Cumulatively, the company has distributed a total of 891 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haohai Biological increased by 7.44% to 8,388, with an average of 0 circulating shares per shareholder [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 5.6048 million shares, an increase of 2.617 million shares from the previous period [3]. Market Activity - On November 26, 2023, Haohai Biological's stock traded at 49.46 yuan per share, with a total market capitalization of 11.503 billion yuan. The trading volume was 38.4425 million yuan, with a turnover rate of 0.40% [1]. - The net outflow of main funds was 1.5809 million yuan, with significant selling activity observed [1].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年11月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售 ...

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has experienced a decline of 15.47% year-to-date, with a slight recovery observed on November 25, where it rose by 2.13% to reach 50.38 CNY per share, indicating potential market interest despite recent downturns [2][1]. Company Overview - Haohai Biological Technology, established on January 24, 2007, and listed on October 30, 2019, is located in Shanghai and specializes in the research, production, and sales of medical devices and pharmaceuticals [2]. - The company's revenue composition includes: 44.12% from medical beauty and wound care products, 28.18% from ophthalmic products, 17.39% from orthopedic products, 8.46% from anti-adhesion and hemostatic products, and 1.86% from other products [2]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion CNY, reflecting a year-on-year decrease of 8.47%, while the net profit attributable to shareholders was 305 million CNY, down 10.63% year-on-year [2]. - The company has distributed a total of 891 million CNY in dividends since its A-share listing, with 557 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 7.44% to 8,388, with an average of 0 shares held in circulation per shareholder [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 5.6048 million shares, an increase of 2.617 million shares compared to the previous period [3]. Market Activity - On November 25, the stock saw a trading volume of 31.1529 million CNY, with a turnover rate of 0.32%, and a net inflow of main funds amounting to 1.7261 million CNY [1].

Core Viewpoint - Social media has become the primary information source for young cosmetic surgery consumers, with a focus on a new injectable material called Calcium Hydroxylapatite (CaHA), which is gaining popularity in the aesthetic market [3][5]. Market Overview - In the global dermal filler market, hyaluronic acid holds a dominant 77% market share, while Calcium Hydroxylapatite accounts for 7% [3]. - Merz Aesthetics' Radiesse is currently the only FDA-approved Calcium Hydroxylapatite facial filler, recently launched in China [5]. Regulatory and Compliance Issues - There are concerns regarding the high prices of these new products, leading to potential exploitation by some cosmetic institutions [6]. - Only two approved products for facial injection in China are Radiesse and Aphranel, while others are approved for non-weight-bearing bone defects [6]. - The use of Calcium Hydroxylapatite in aesthetic applications must adhere to strict regulatory standards, with a clear distinction between products intended for medical and aesthetic use [9]. Consumer Awareness and Safety - Consumers are advised to be cautious and verify the legitimacy of products before use, as many products are not intended for aesthetic applications [8][10]. - Misleading advertising and unverified information on social media pose significant risks to consumers, particularly younger individuals [10]. - The importance of using qualified medical professionals for injections is emphasized, as improper techniques can lead to serious complications [10].

Core Viewpoint - Social media has become the primary information source for young cosmetic consumers, with a growing interest in calcium hydroxyapatite (CaHA) as a regenerative injectable material, often referred to as the "hardest hyaluronic acid" [1] Market Overview - Hyaluronic acid currently holds a dominant 77% market share in the global dermal filler market, while calcium hydroxyapatite accounts for 7% [1] - Merz Aesthetics' Radiesse is the only FDA-approved calcium hydroxyapatite facial filler in the global market, recently approved in China [2] - Domestic companies such as Haohai Biological Technology, Huaxi Biological, and Juzhi Biological are actively developing calcium hydroxyapatite products, intensifying market competition [2] Regulatory and Safety Concerns - Only two calcium hydroxyapatite products are approved for facial injection in China, highlighting the limited scope of approved applications [2] - The use of calcium hydroxyapatite in cosmetic procedures is subject to strict regulatory oversight, requiring clinical trials for injectable products, which can take 6 to 7 years for approval [4] - There are concerns regarding the misuse of calcium hydroxyapatite products, with reports of unqualified products being injected in medical aesthetic clinics [2][4] Consumer Awareness and Risks - The medical aesthetic market faces challenges with misleading advertising and the promotion of unapproved products, leading to potential consumer harm [6] - Experts emphasize the importance of consumers verifying the legitimacy of products and the qualifications of practitioners before undergoing treatments [5][6] - The industry is marked by a disconnect between regulatory bodies, manufacturers, and medical aesthetic institutions, complicating compliance and consumer safety [4]

Core Viewpoint - Recent consumer complaints regarding unqualified products used in medical beauty clinics have sparked discussions about the off-label use of calcium hydroxyapatite (CaHA) aesthetic products [1][2] Industry Overview - Social media has become the primary information source for young consumers in the medical beauty sector, with many influencers promoting CaHA as a regenerative injection material [1] - In the global dermal filler market, hyaluronic acid holds a dominant 77% market share, while CaHA accounts for 7% [1] Product Approval and Market Competition - Merz Aesthetics' Radiesse is currently the only FDA-approved CaHA facial filler, which received approval from China's drug regulatory authority in March and has recently launched in the domestic market [2] - Domestic companies such as Haohai Biological Technology, Huaxi Biological, and Juzhi Biological are actively developing CaHA products, intensifying market competition [2] Regulatory and Safety Concerns - Only two approved CaHA fillers in China are indicated for facial injection, while others are approved for non-load-bearing bone defects [2] - The safety of CaHA as a biomaterial has been established since the 1970s, but its off-label use can lead to complications such as inflammation and nodules [3] Consumer Awareness and Risks - Approximately 200 CaHA products have been approved in China, primarily for orthopedic and dental use, not for aesthetic applications [4] - The regulatory framework requires medical devices and drugs to undergo strict classification and approval processes, but some manufacturers may use misleading marketing strategies [5] Recommendations for Consumers - Consumers are advised to seek treatment from reputable institutions and verify product authenticity before procedures [6] - Medical professionals performing CaHA injections must have the necessary qualifications and training to minimize risks [6] - Misleading advertising and unverified information on social media pose significant risks to consumers, particularly younger individuals [6]

呈交日期： 2025年11月24日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...